Gender‐affirming hormone therapy and the risk of sex hormone‐dependent tumours in transgender individuals—A systematic review

@article{McFarlane2018GenderaffirmingHT,
  title={Gender‐affirming hormone therapy and the risk of sex hormone‐dependent tumours in transgender individuals—A systematic review},
  author={Thomas McFarlane and J. Zajac and A. Cheung},
  journal={Clinical Endocrinology},
  year={2018},
  volume={89},
  pages={700 - 711}
}
Cancers are a leading cause of death worldwide, and transgender individuals are no exception. The effects of gender‐affirming hormone therapy (GAHT) on sex hormone‐dependent tumours are unclear. Therefore, this review seeks to determine whether tumour risk in transgender individuals differs from the general population, to guide clinical screening recommendations. 
View on Wolters Kluwer
onlinelibrary.wiley.com
16 Citations
Background Citations
3

16 Citations

Citation Type

Citation Type

Position statement on the hormonal management of adult transgender and gender diverse individuals
TLDR
This work aims to provide general practitioners, physicians and other medical professionals with specific Australian recommendations for the hormonal and related management of adult TGD individuals. Expand
Testosterone therapy considerations in estrogen, progesterone and androgen receptor positive breast cancer in a transgender male.
TLDR
A 44-year-old premenopausal individual assigned female at birth but with a male gender identity, presented requesting masculinizing hormone therapy for long-standing gender dysphoria, and baseline blood tests and hormonal panel were within female reference ranges. Expand
Effects of antiandrogens on prolactin levels among transgender women on estrogen therapy: A systematic review
Gender-affirming hormone therapy for transgender women includes estrogen and antiandrogens (cyproterone acetate, spironolactone, or gonadotropin-releasing hormone agonists). Both estrogen and antia...
Health considerations for transgender women and remaining unknowns: a narrative review
TLDR
This narrative review aims to comprehensively summarize health considerations for transgender (trans) women and identify TW-related research areas that will provide answers to remaining unknowns surrounding TW’s health. Expand
Inclusion of transgender and gender diverse health data in cancer biorepositories
TLDR
This narrative review synthesized the current published literature regarding the inclusion of TGD health data in cancer biorepositories and cancer research conducted on biospecimens to propose strategies to address the inequities in TGD tissue-based research and diversify the field of biobanking as a whole. Expand
Approach to Interpreting Common Laboratory Pathology Tests in Transgender Individuals
TLDR
It is proposed that once individuals have commenced gender-affirming hormone therapy, the reference range of the affirmed gender be reported except for PSA or cardiac troponin, which are dependent on organ size. Expand
What Oncologists Should Know About Treating Sexual and Gender Minority Patients With Cancer
Sexual and gender minority (SGM) individuals encompass a broad spectrum of sexual orientations and gender identities. Although SGM is a research term, this population is often known as lesbian, gay...
Cancer screening in the transgender population: a review of current guidelines, best practices, and a proposed care model.
TLDR
Current guidelines and practice patterns of cancer screening in transgender patients are covered, and evidence-based data is lacking, to draw from cis-gender screening guidelines to suggest best-practice screening approaches for transgender patients. Expand
Gender affirming medical care of transgender youth.
TLDR
It is important for providers to understand that desire for medical interventions is variable among persons and that a discussion about individual desires for surgical options is recommended. Expand
Biomedical issues in transgender health research
Transgender is an umbrella term that refers to those individuals whose gender identity (i.e. the person’s internal sense of gender) differs from the sex assigned at birth. Although the main… Expand
...
1
2
...

References

SHOWING 1-10 OF 75 REFERENCES
Triple negative breast cancer in a male‐to‐female transsexual
TLDR
A case of an aggressive triple negative inflammatory breast cancer in a male‐to‐female transsexual with a complicated psychiatric history with significant antipsychotic use is reported. Expand
Mortality and morbidity in transsexual subjects treated with cross‐sex hormones
TLDR
Investigation of mortality and morbidity figures in a large group of transsexual subjects receiving cross‐sex hormone treatment finds that the optimum steroid hormone treatment regimes for transsexual subjects has not yet been established. Expand
The Development of Prostate Adenocarcinoma in a Transgender Male to Female Patient: Could Estrogen Therapy Have Played a Role?
TLDR
Long standing beliefs of androgen suppression conferring a protective effect against prostate cancer development have been challenged by the literature citing adenocarcinoma development in the prostate of rodent models following combined estrogen and testosterone treatment. Expand
Breast cancer in female-to-male transsexuals: two cases with a review of physiology and management.
TLDR
2 cases of breast cancers diagnosed in FtM transsexuals who have been treated with supraphysiological doses of testosterone are described and possible roles of testosterone in the development of breast cancer are examined. Expand
Metastatic prostate cancer in transsexual diagnosed after three decades of estrogen therapy.
TLDR
A male-to-female transgender woman who was diagnosed with metastatic prostate cancer, 31 years post-feminization is reported, a challenge in the treatment and follow-up of such patients. Expand
Breast cancer in male-to-female (MtF) transgender patients: is hormone receptor negativity a feature?
TLDR
A 41-year-old male-to-female (MtF) transgender patient presented with a symptomatic tender lump in the left breast and was referred to the oncologist for adjuvant chemotherapy and radiotherapy. Expand
Hormone-related tumors in transsexuals receiving treatment with cross-sex hormones.
TLDR
The probability of a hormone-related tumor increases with the duration of exposure to cross-sex hormones and the aging of the population of transsexuals, so far only a few cases of hormone- related cancer in transsexuals are encountered. Expand
Five new cases of breast cancer in transsexual persons
TLDR
For adequate treatment and decisions on further cross‐sex hormone treatment it is important to have information on the staging and histology of the breast tumour (type, grade and receptor status), with an upcoming role for the androgen receptor status, especially in FtoM transsexual subjects with breast cancer who receive testosterone administration. Expand
Breast cancer development in transsexual subjects receiving cross-sex hormone treatment.
TLDR
Cross-sex hormone treatment of transsexual subjects does not seem to be associated with an increased risk of malignant breast development, in either MtF or FtM transsexual individuals. Expand
Recurrence and Progression of Meningioma in Male-to-Female Transgender Individuals During Exogenous Hormone Use
TLDR
This report describes the third published case of a de novo World Health Organization Grade I meningioma occurring in a male-to-female transgender individual using exogenous hormones, and suggests that this association creates a relative contraindication for hormonal therapy in patients with diagnoses of mening ioma. Expand
...
1
2
3
4
5
...